| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8bfaaebf5eaafdc2404f7ce9221b19c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1080624556f7dc15ab076cc5d982b85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f30eaf526fcaaae821ba7a071c0fa01c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e579d7fdff4bbf1cca6d3f5170a5dcc2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 |
| filingDate |
2009-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bba8a1607de1d7c8448b785afb056620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c2a079333ce3f6c1070c5e1e8bb6f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_520a552574a76189e68cdb46a412941c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f225b3bfc07a6ff4153f9bf7c136549 |
| publicationDate |
2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011200554-A1 |
| titleOfInvention |
Therapeutic agent for hepatitis c |
| abstract |
A novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C is disclosed. The therapeutic agent for hepatitis C contains as an effective ingredient hydroxyurea. The therapeutic agent for hepatitis C optionally further contains interferon α. By the present invention, a novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C was provided. A synergistic therapeutic effect against hepatitis C is obtained by using interferon α in combination. Therefore, in cases where a patient is infected with the genotype of hepatitis C virus for which therapy by interferon α is effective, the therapeutic effect is further promoted by using interferon α in combination. |
| priorityDate |
2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |